Ikeda S, et al. - A trial of a combination therapy of bevacizumab, cisplatin, and docetaxel was carried out in chemotherapy-naive Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Despite the high incidence of grade 3/4 neutropenia, high effectiveness of a combination therapy of bevacizumab, cisplatin, and docetaxel, followed by bevacizumab as maintenance, was reported in patients with non-squamous NSCLC. In addition, the efficacy of the bevacizumab-contained treatment regimen may be predicted by the increase in circulating endothelial cell count between days 1 and 8.